MANGOCEUTICALS, INC.
Mangoceuticals connects consumers with licensed healthcare professionals through its MangoRX website and telehealth platform, and develops, markets and sells men’s wellness products and services. Its brands include Mango for erectile dysfunction, Grow for hair loss, Mojo for hormone balance and therapy, and Slim for weight loss. These compounded products are prescribed by physicians and fulfilled by Epiq Scripts, a related-party compounding pharmacy. Mangoceuticals also markets Prime, a prescription oral testosterone replacement therapy powered by Kyzatrex. The platform connects customers with medical providers and a pharmacy for consultations, prescriptions and product fulfillment. Customers pay Mangoceuticals for prescribed products, and the company offers subscription purchases billed on a recurring basis. Mangoceuticals is headquartered in Dallas, Texas.
No SEC Form 4 filings for $MGRX in the last 30 days.
See all $MGRX insider activity →MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 3.03. Material Modification to Rights of Security Holders. As described in Item 5.03 , which is incorporated by reference into this Item 3.03 , Mangoceuticals, Inc. (the “ Company ”) amended its Series B and Series C preferred stock designations effective November 9, 2026, a
Mangoceuticals (MGRX) filed to issue up to 1M shares of Series D preferred stock at $10 each, raising up to $10M. The stock will be tokenized on T7X's blockchain, with 8% annual dividends. Conversion to common stock is possible after 3 years. Proceeds will fund general corporate purposes. The SEC has not yet qualified the offering.
Mangoceuticals (MGRX) received approval for a potential $10M Series D offering of 1M shares at $10 each. The Series D stock has senior rights over common shares. The company may not proceed, and no filings are effective yet. The annual meeting is set for December 30, 2026, with a record date of November 12, 2026.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MGRX (MANGOCEUTICALS, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent MGRX coverage spans corporate actions, macro economy and earnings.
New senior preferred shares increase dilution risk and may pressure the common stock.
The tokenized preferred offering introduces dilution risk and may pressure the stock, though the novel blockchain structure could attract niche investors.
The approval may lead to dilution and senior liquidation preference pressure on common stock.
Potential dilution and new capital raise may pressure the stock.
The small capital raise may cause modest dilution and slight downward pressure on the stock.
AlphAI scores every news story that mentions MGRX with an AI model for sentiment and relevance, and aggregates insider trades from MANGOCEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 3.03. Material Modification to Rights of Security Holders. As described in Item 5.03 , which is incorporated by reference into this Item 3.03 , Mangoceuticals, Inc. (the “ Company ”) amended its Series B and Series C preferred stock designations effective November 9, 2026, a
Mangoceuticals (MGRX) filed to issue up to 1M shares of Series D preferred stock at $10 each, raising up to $10M. The stock will be tokenized on T7X's blockchain, with 8% annual dividends. Conversion to common stock is possible after 3 years. Proceeds will fund general corporate purposes. The SEC has not yet qualified the offering.
Mangoceuticals (MGRX) received approval for a potential $10M Series D offering of 1M shares at $10 each. The Series D stock has senior rights over common shares. The company may not proceed, and no filings are effective yet. The annual meeting is set for December 30, 2026, with a record date of November 12, 2026.
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On November 2, 2026, the holder of all 50 issued and outstanding shares of Series B Convertible Preferred Stock (the “ Series B Preferred Stock ”) of Mangoceuticals, Inc. (the “ Company ”), acting by written consent
Mangoceuticals (MGRX) announced a registered direct offering to raise $492,750 by selling 657,000 shares and warrants. The warrants are exercisable at $1.00 per share and expire in five years. Proceeds will be used for working capital and general corporate purposes, with the offering expected to close on Oct 9, 2026.
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX / October 9, 2026 / M
Mangoceuticals, Inc. (MGRX) completed a $500K direct offering at $0.75 per unit, a 74% premium over the referenced closing price. Each unit consists of one share and one warrant. The company filed details in an Oct. 9, 2026 Form 8-K. The offering is part of recent funding efforts, with potential catalysts including additional funding, warrant exercises, or revenue milestones.
U.S. stock futures rose Friday after a weaker-than-expected September jobs report, with nonfarm payrolls adding 29,000 jobs vs. 90,000 expected. Nike (NKE) fell over 10% premarket after mixed earnings, while Synaptics (SYNA) surged 14.45% on an acquisition deal. The 10-year Treasury yield was at 5.24%, and markets priced in a 23.8% chance of a Fed rate hike in October.
Nike Inc (NKE) reported Q1 revenue of $11.21B, missing estimates of $11.33B, but beat EPS estimates. Shares fell 9.5% in pre-market trading. Other stocks like Roze AI (RZAI) and Mangoceuticals (MGRX) also declined.
Mangoceuticals' subsidiary MangoRx IP Holdings raised $2.5 million from two investors to commercialize its antiviral patent portfolio. The investment, paid in two tranches, gives investors a 25% stake in the subsidiary. The funds will support the development of MGX-0024, an antiviral technology with applications in animal and human health. The company's stock closed at $0.48 on Thursday, up 12.24%.
